We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Researchers Stress Cancer Cells for Better Treatment Options

By LabMedica International staff writers
Posted on 10 Dec 2014
Employing metabolic stress to destroy cancer cells could create new approaches for better targeted therapies that will not hurt normal cells and have no unpleasant side effects. More...


Researchers from the University of Adelaide in South Australia (Adelaide) revealed that chromosomal instability, which is a major characteristic of quickly dividing cancer cells, makes them stressed and susceptible to mild metabolic disruption.

Metabolism is the normal process by which the body converts food into energy. “A common problem in treating cancers is that they don’t respond to chemotherapy, or they respond for a while, but then come back,” stated lead author Dr. Stephen Gregory, senior postdoctoral fellow with the University’s School of Molecular and Biomedical Sciences.

“One reason this happens is because a tumor is usually not made up of identical cells but rather a diverse population of cells that changes all the time, losing, and gaining chromosomes as they divide—so-called chromosomal instability. Sooner or later they change enough to be able to resist chemotherapy drugs. Our research has shown that chromosomal instability has some consequences for cells—they get stressed, and it only takes a small metabolic push to kill them.”

Traditional chemotherapy is also very toxic to all dividing cells, especially affecting cells in hair follicles, blood, and the gut lining, frequently causing hair loss, pain, and making patients unwell. “We need to find ways to target cancer cells without affecting other normal dividing cells,” said Dr. Gregory.

The researchers stimulated chromosomal instability in the fly Drosophila and discovered that the unstable cells were “on the edge” of how much stress they could endure. “This is significant because a change in metabolism is something people cope with very well normally,” said Dr. Gregory. “That means that we hope to be able to develop treatments that have no side effects on patients, but are able to kill off the unstable tumor cells that cause relapses.”

Dr. Gregory noted that this may give some support to hypotheses of alternative treatments such as going on a drastic diet. “People who have advanced cancer which isn’t responding to chemotherapy often try a range of different treatments such as a radical diet in the hope it may help,” he said. “In some situations, it may in fact work; but we hope to be able to point the way to a more targeted approach—finding the most appropriate steps for intervention in the metabolic process that will give the best results.”

The research was published October 27, 2014, in the journal Oncogene.

Related Links:

University of Adelaide in South Australia



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.